EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Dapagliflozin attenuates diabetic renal fibrosis by inhibiting macrophage-myofibroblast transition via the TGF-β1-Smad3/7 pathway

Xiaoyun Li, Guoxiang Yao, Honggang Wang, Tingting Zhao, Yujiao Sun, Qi Gao, Zhuo Li, Bing Chen

PeerJ · 03.06.2026 · 14 · e21321

DOI: 10.7717/peerj.21321 ↗

Kurz gefasst

Fachartikel in der Zeitschrift PeerJ, online erschienen am 03.06.2026. Verfasst von Xiaoyun Li und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nephrology, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, Shandong, China. Hauptthemen laut MEDLINE: Glucosides, Diabetic Nephropathies, Macrophages, Benzhydryl Compounds. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 71 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Shandong Natural Science Foundation, National Natural Science Foundation of China Youth Science Fund Project, Shandong Provincial Traditional Chinese Medicine Science and Technology Project.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

Renal fibrosis plays a pivotal role in the progression of renal dysfunction in diabetic kidney disease (DKD), with the macrophage-to-myofibroblast transition (MMT) serving as a central mechanism driving the advancement of renal fibrosis to end-stage renal disease (ESRD) in various chronic kidney conditions. Although the sodium-glucose cotransporter 2 (SGLT2) inhibitor dapagliflozin (DAPA) slows renal function decline in DKD, its antifibrotic mechanisms remain unclear. This study aimed to elucidate whether DAPA ameliorates renal fibrosis by suppressing MMT, and the underlying molecular mechanisms.

Methods

We established a DKD model in male C57BL/6J mice by inducing them with a high-fat diet (HFD) followed by streptozotocin (STZ) injection. The effects of DAPA on renal function parameters (serum creatinine (Scr), urinary albumin-to-creatinine ratio (UACR)), and renal pathological injury, fibrosis markers (α-smooth muscle actin (α-SMA), type I collagen (Col-I)) were comprehensively evaluated. Immunofluorescence (IF) and Western blot were employed to analyze MMT progression (F4/80 + /α-SMA + double-positive cells) and TGF-β1-Smad3/7 pathway activity.

Results

DAPA significantly reduced blood glucose levels, mitigated weight loss, and effectively inhibited type 2 diabetes-induced increase in Scr (43.78 ± 3.84 vs. 33.93 ± 6.77 µmol/L, P < 0.05) and UACR (89.17 ± 16.33 vs. 52.51 ± 10.51 mg/g, P < 0.05) in DKD mice. DAPA significantly attenuated glomerular hypertrophy, mesangial hyperplasia, and vacuolar degeneration of the tubular epithelium in DKD mice, while concurrently reducing glomerular and tubular injury scores, as well as the renal interstitial fibrosis area ( P < 0.05). IF revealed increased MMT within the renal tubulointerstitium in DKD mice, accompanied by elevated deposition of α-SMA and Col-I. DAPA treatment markedly reduced F4/80 + macrophage infiltration and F4/80 + /α-SMA + and F4/80 + /Col-I + double-positive MMT cells, with decreased α-SMA and Col-I expression ( P < 0.05). Additionally, TGF-β1 and phosphorylated Smad3 (p-Smad3) expression were significantly upregulated in DKD mice, whereas Smad7 was downregulated ( P < 0.05). DAPA treatment significantly reduced TGF-β1 and p-Smad3 levels and restored Smad7 expression, rebalancing the Smad3/Smad7 axis ( P < 0.05). Therefore, we propose that DAPA likely alleviates renal fibrosis in DKD by modulating renal TGF-β1 activity and restoring the Smad3/Smad7 balance, thereby suppressing MMT.

Conclusion

This study is the first to reveal that DAPA is highly likely to exert anti-fibrotic effects through a novel mechanism involving targeted modulation of the TGF-β1-Smad3/7 axis to inhibit MMT, thereby laying a theoretical foundation and identifying a potential therapeutic target for precision treatment of DKD.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

GlucosidesDiabetic NephropathiesMacrophagesBenzhydryl CompoundsMyofibroblastsSodium-Glucose Transporter 2 InhibitorsAnimalsTransforming Growth Factor beta1MaleSmad3 ProteinMice, Inbred C57BLMiceFibrosisDiabetes Mellitus, ExperimentalSignal TransductionSmad7 ProteinKidney

Stichwörter der Autor:innen

DapagliflozinDiabetic kidney diseaseMacrophage-myofibroblast transition (MMT)Renal fibrosisTGF-β1/Smad

Substanzen

GlucosidesTransforming Growth Factor beta1Smad3 ProteinSmad3 protein, mousedapagliflozinBenzhydryl CompoundsSmad7 ProteinSmad7 protein, mouseTgfb1 protein, mouseSodium-Glucose Transporter 2 Inhibitors

Autor:innen und Institutionen

  • Department of Nephrology, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, Shandong, China.
  • Department of Nephrology, The Second Qilu Hospital of Shandong University, Jinan, Shandong, China.
  • Department of Respiratory and Critical Care Medicine, Shandong Public Health Clinical Center, Shandong University, Jinan, Shandong, China.

Förderung

  • Shandong Natural Science Foundation
  • National Natural Science Foundation of China Youth Science Fund Project
  • Shandong Provincial Traditional Chinese Medicine Science and Technology Project

Zitieren

APA

Li, X., Yao, G., Wang, H., Zhao, T., Sun, Y., Gao, Q., Li, Z., & Chen, B. (2026). Dapagliflozin attenuates diabetic renal fibrosis by inhibiting macrophage-myofibroblast transition via the TGF-β1-Smad3/7 pathway. PeerJ, 14, e21321. https://doi.org/10.7717/peerj.21321

Vancouver

Li X, Yao G, Wang H, Zhao T, Sun Y, Gao Q, et al. Dapagliflozin attenuates diabetic renal fibrosis by inhibiting macrophage-myofibroblast transition via the TGF-β1-Smad3/7 pathway. PeerJ. 2026;14:e21321. doi:10.7717/peerj.21321

BibTeX
@article{Li2026,
  author = {Li, Xiaoyun and Yao, Guoxiang and Wang, Honggang and Zhao, Tingting and Sun, Yujiao and Gao, Qi and Li, Zhuo and Chen, Bing},
  title = {Dapagliflozin attenuates diabetic renal fibrosis by inhibiting macrophage-myofibroblast transition via the TGF-β1-Smad3/7 pathway},
  journal = {PeerJ},
  year = {2026},
  volume = {14},
  pages = {e21321},
  doi = {10.7717/peerj.21321}
}
Kostenlos starten →